Adagene

Yahoo Finance • 7 hours ago

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patientswith and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration p... Full story

Yahoo Finance • 7 hours ago

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotugachieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/39) in the combined 10... Full story

Yahoo Finance • 21 hours ago

Adagene ADR Non-GAAP EPS of -$0.24 beats by $0.41, revenue of $7.7M beats by $6.03M

* Adagene ADR press release [https://seekingalpha.com/pr/20460114-adagene-reports-full-year-2025-financial-results-and-provides-corporate-update] (ADAG [https://seekingalpha.com/symbol/ADAG]): FY Non-GAAP EPS of -$0.24 beats by $0.41.... Full story

Yahoo Finance • 21 hours ago

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotugshowed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months... Full story

Yahoo Finance • 16 days ago

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastot... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene Inc. Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: A... Full story

Yahoo Finance • 5 months ago

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which Third Arc Bio will... Full story

Yahoo Finance • 7 months ago

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 w... Full story

Yahoo Finance • 7 months ago

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos a... Full story

Yahoo Finance • 7 months ago

Adagene to Participate in Two Investor Conferences in September

SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s... Full story

Yahoo Finance • 8 months ago

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements. Company expects to beg... Full story

Yahoo Finance • 9 months ago

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZ... Full story

Yahoo Finance • 9 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company trans... Full story

Yahoo Finance • 9 months ago

Adagene gains as Sanofi collaboration expands

[Collaboration concept in word tag cloud] rafal_olechowski * Adagene (NASDAQ:ADAG [https://seekingalpha.com/symbol/ADAG]) ADRs added ~16% in the premarket on Tuesday after Sanofi (NASDAQ:SNY [https://seekingalpha.com/symbol/SNY]) expand... Full story

Yahoo Finance • 9 months ago

Adagene announces up to $25 million strategic investment from Sanofi

- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, 2025 (GLOBE NEWSWIR... Full story

Yahoo Finance • 10 months ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy... Full story

Yahoo Finance • 10 months ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable... Full story

Yahoo Finance • 11 months ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASC... Full story

Yahoo Finance • last year

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T cell engagers for potentially superior... Full story